Absence of structural or functional alterations in male and female reproductive organs of F1 and F2 generations derived from female mice exposed to 3'-azido-3'-deoxythymidine during pregnancy.
To investigate the effects of in utero exposure to 3'-azido-3'-deoxythymidine (AZT) on male and female reproductive system development, pregnant CD-1 mice were given daily intragastric doses of 25.0 mg AZT during days 12 through 18 of gestation. The offspring were examined at birth, as well as at pubertal, young adult and adult stages of development, for reproductive organ endpoints including anogenital distance, onset of testicular descent, latency to vaginal opening, and proportion of time for each of the stages of estrous cycle. These reproductive endpoints remained mostly unchanged in AZT-treated offspring as compared to the controls. Males and females exposed in utero to AZT (F1 generation) were fertile when mated to untreated females and males, respectively, and their liveborn F2 offspring showed no adverse effects for any of the reproductive parameters tested. Thus, no evidence of developmental reproductive toxicity was noted either in the F1 mice exposed to AZT during the critical period of male and female reproductive system development, or in the F2 mice born of matings between the AZT-exposed F1 mice and unexposed animals.
Diwan
B A
BA
Intramural Research Support Program, SAIC Frederick, NCI-Frederick Cancer Research Development Center, MD 21702-1201, USA. bdiwan@mail.ncifcrf.gov
Olivero
O A
OA
Poirier
M C
MC
D000014:Abnormalities, Drug-Induced; D000818:Animals; D019380:Anti-HIV Agents / Q000633:toxicity*; D005260:Female; D005298:Fertility / Q000187:drug effects; D005835:Genitalia / Q000002:abnormalities / Q000187:drug effects*; D008297:Male; D051379:Mice; D009929:Organ Size / Q000187:drug effects; D011247:Pregnancy; D011256:Pregnancy Outcome; D011297:Prenatal Exposure Delayed Effects; D018894:Reverse Transcriptase Inhibitors / Q000633:toxicity; D015215:Zidovudine / Q000633:toxicity*
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine